ArticleResearch square2026
Sigma1 Receptor Activation Confers Durable Neuroprotection Following Neonatal Ischemic Retinal Injury.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness. Although current therapies effectively suppress pathological neovascularization, many patients continue to exhibit persistent visual dysfunction despite regression of active disease, highlighting an unmet need for neuroprotective interventions. Sigma 1 receptor (Sig1R), an endoplasmic reticulum-mitochondrial chaperone and regulator of cellular stress responses, has emerged as a promising therapeutic target in neurodegenerative and retinal diseases. Here, we investigated whether Sig1R activation confers sustained neuroprotection following neonatal ischemic retinal injury. Wild-type and Sig1R knockout mice were subjected to oxygen-induced retinopathy (OIR) and treated systemically with the high-affinity Sig1R agonist (+)-pentazocine [(+)-PTZ]. Retinal structure and visual function were assessed longitudinally through 20 weeks of age using visual acuity, contrast sensitivity, electroretinography (ERG), pattern ERG (PERG), spectral-domain optical coherence tomography (SD-OCT), and histological analyses. Chronic Sig1R activation significantly preserved visual acuity, contrast sensitivity, rod- and ganglion cell-mediated retinal function, retinal ganglion cell survival, and inner retinal architecture in OIR mice. These protective effects were abolished in Sig1R-deficient mice, demonstrating a requirement for Sig1R in mediating neuroprotection. Mechanistically, Sig1R activation reduced apoptotic signaling, attenuated oxidative and nitrosative stress, improved mitochondrial respiratory function, and enhanced endogenous antioxidant pathways. Collectively, these findings demonstrate that Sig1R activation provides durable, receptor-dependent neuroprotection following neonatal ischemic retinal injury by coordinating redox, mitochondrial, and cell-survival pathways. These results identify Sig1R as a promising therapeutic target for preserving retinal neuronal integrity and long-term visual function in retinopathy of prematurity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.